Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for ChromaDex Corp. (CDXC:NASDAQ), powered by AI.
ChromaDex Corp. is currently trading at $3.45. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for ChromaDex Corp. on Alpha Lenz.
View ChromaDex Corp.'s valuation metrics on Alpha Lenz.
“ChromaDex Corp.'s ROE is 22.9%. Explore profitability and growth together.”
Ask for details →ChromaDex Corp. is a bioscience company that specializes in research, development, and marketing of evidence-based products and ingredients derived from its proprietary technology. The company's primary focus is on the production and commercialization of dietary supplements designed for healthy aging, with a notable product known as Tru Niagen, a supplement aimed at boosting cellular health through its unique nicotinamide riboside chloride formulation. ChromaDex Corp. leverages partnerships with academic and clinical institutions to stay at the forefront of scientific advancements in the field of nutrients and supplements. This strategic approach allows the company to maintain compliance with strict regulatory standards while ensuring the efficacy of its product offerings. By operating within the intersection of health, wellness, and biotechnology, ChromaDex Corp. plays a critical role in the rapidly evolving nutraceutical sector, striving to meet the increasing consumer demand for science-backed health solutions. Its contributions to the market emphasize the potential of biotechnology in enhancing public health and well-being.
“ChromaDex Corp.'s ROE is 22.9%. Explore profitability and growth together.”
Ask for details →ChromaDex Corp. (ticker: CDXC) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 104 employees.
The current price is $3.45 with a P/E ratio of -x and P/B of -x.
ROE is 22.94% and operating margin is 7.76%. Annual revenue is $100M.